Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript

Aug 21, 2020 / 02:30PM GMT
Operator

Good morning and good afternoon, and welcome to the Kesimpta FDA Approval Investor Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) A recording of the conference, including the Q&A session, are available on our website shortly after the call ends. (Operator Instructions)

With that, I would like to hand over to Samir Shah, Global Head, Investor Relations. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you very much, and good morning and good afternoon, everybody. Welcome to the Kesimpta approval call. First of all, I'd like to say a big thank you for taking the time to participate on a Friday afternoon. We appreciate you're busy, and we appreciate the time that you're actually taking to listen to the presentation. We hope the presentation's of interest to you and we can clarify any of the outstanding issues or questions that you may have.

With us on the call, we have Marie-France Tschudin. She, as you know, is the Head of the Pharmaceutical division for Novartis. We also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot